Why Is It Critical to Embed Lifecycle Management in Your Combination Products Development?
2nd Combination Products Lifecycle Management, Boston, April 23:
Increasingly fierce competition amongst pharma/biotechs and R&D costs have made drug and device developers re-think their approaches. Developing a unique and patient centric combination product will ultimately offer a longer life-span with a commercial advantage.
Integrating lifecycle management (LCM) during the R&D phase, and aligning both drug and device teams to have a common mindset have re-configured how combination product development should look like – which can also shorten timeline, reduce costs and risks, and enhance patient experience.
The 2nd Combination Products Lifecycle Management in Pharma will gather 100+ senior leaders from Product Development, Quality, Regulatory Affairs on June 25 – 27 in Boston to discuss the benefits and lessons learned in such transformation. Leading speaker line-up includes the FDA, Sanofi, Kaleo, Novartis AG, EMD Serono, Alnylam Pharmaceuticals, Bayer, Merck and many others. Innovation Partners Minnetronix Medicals and Dassault Systems will also demonstrate their expertise insights and platforms in product lifecycle management.
For more information, please visit https://ter.li/l1qfmh or contact a team member on +1 617 455 4188 or email info@hansonwade.com.
This event is supported by Minnetronix Medical and Dassault Systems.